Best Treatment for HR+/HER2+ Breast Cancer
Author Information
Author(s): Liu Shiwei, Yu Miao, Mou Exian, Wang Meihua, Liu Shuanghua, Xia Li, Li Hui, Tang Hao, Feng Yajing, Yu Xin, Mi Kun, Wang Hao
Primary Institution: Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China
Hypothesis
What is the optimal neoadjuvant treatment strategy for HR+/HER2+ breast cancer?
Conclusion
Trastuzumab plus pertuzumab is the best neoadjuvant treatment for HR+/HER2+ breast cancer, with anthracycline-free carboplatin-containing chemotherapy also showing promise.
Supporting Evidence
- 20 trials with 2809 patients were included in the primary pCR analysis.
- HP+C demonstrated a significantly higher pCR rate compared to H+C.
- H+TKI+C achieved a higher pCR rate than both H+C and L+C.
- Anthracycline-free regimens showed a marginally higher pCR rate than anthracycline-containing regimens.
- Pertuzumab with trastuzumab ranked first in EFS analysis.
Takeaway
Doctors found that a combination of two medicines, trastuzumab and pertuzumab, works best for treating a specific type of breast cancer before surgery.
Methodology
A systematic review and network meta-analysis of trials comparing neoadjuvant regimens for HR+/HER2+ breast cancer.
Potential Biases
One trial had a high overall risk of bias due to missing randomization; most trials had low risk.
Limitations
The EFS analysis included only five trials, limiting robustness, and safety analysis was not conducted due to insufficient data.
Participant Demographics
Included 2809 patients with HR+/HER2+ breast cancer.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website